Mayo, Advanced Biological Laboratories to Develop NGS Diagnostics | GenomeWeb

NEW YORK (GenomeWeb) – Mayo Medical Laboratories will collaborate with Advanced Biological Laboratories to develop a next-generation sequencing pipeline for laboratory-developed diagnostic tests.

Under the terms of agreement, the Mayo Clinic Division of Clinical Microbiology will select the clinical samples on which the tests will be validated, while ABL will lead development of information technology. ABL is a Luxembourg-based medical data technology company that develops information technology and health solutions for patient management and sequencing data analysis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.